共 113 条
[11]
Zalewski A(2014)Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial Jama 312 1006-683
[12]
Zalewski A(2019)ESC guidelines 2019 on chronic coronary syndrome (CCS, previously "stable coronary artery disease") : What is new? What is particularly important? Herz 44 676-420
[13]
Macphee C(2015)Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population BMC Cardiovasc Disord 15 14-331
[14]
Tousoulis D(2009)Lipoprotein-associated phospholipase a (2) and atherosclerosis Curr Opin Lipidol 20 415-1641
[15]
Papageorgiou N(2013)Lipoprotein-associated phospholipase A2 (Lp-PLA (2)): a novel and promising biomarker for cardiovascular risks assessment Dis Markers 34 323-1525
[16]
Androulakis E(2008)The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 1632-1544
[17]
Stefanadis C(2013)Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe Circ J 77 1518-1003
[18]
Ballantyne CM(2010)Lipoprotein-associated phospholipase a (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 1536-2721
[19]
Hoogeveen RC(2006)Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death Am Heart J 152 997-936
[20]
Bang H(2007)Local production of lipoprotein-associated phospholipase A2 and Lysophosphatidylcholine in the coronary circulation association with early coronary atherosclerosis and endothelial dysfunction in humans Circulation 115 2715-978